Full Text View
Tabular View
No Study Results Posted
Related Studies
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
This study has been completed.
Study NCT00095654   Information provided by Gerstein, Hertzel, MD

First Received on November 5, 2004.   Last Updated on November 9, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Impaired Glucose Tolerance
Cardiovascular Disease
Glucose Metabolism Disorders
Additional conditions recognized in this trial
Cardiovascular Diseases
Glucose Intolerance
Metabolic Diseases
More general conditions related to this trial
Hyperglycemia
Interventions listed in this trial
Ramipril
Rosiglitazone
More general drug interventions related to this trial
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Cardiovascular Agents
Enzyme Inhibitors
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Gerstein, Hertzel, MD
Canadian Institutes of Health Research (CIHR)
Aventis Pharmaceuticals
GlaxoSmithKline
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services